Comparing the current results to its competitors, Atossa Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 1434.38 %, recorded in the same quarter.
December 12, 2024
Unlocking New Frontiers in Breast Cancer Treatment: Synergistic Therapies and Clinical Advances by Atossa TherapeuticsIn a significant stride toward innovative cancer treatment, Atossa Therapeutics, Inc. a clinical-stage biopharmaceutical firm, is making waves in the oncological community with its cutting-edge research and clinical trials aimed at improving outcomes for breast cancer patients. At the forefront of these efforts is their exploration of (Z)-endoxifen as a key therapeutic agent.Atossa is set to present a remarkable advancement in breast cancer treatment at the upcoming 2024 San Antonio Breast Cancer Symposium. The company will unveil findings from a pioneering study that utilized insilico and c...
November 4, 2024
Atossa Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology, has recently reported significant developments related to its lead candidate, (Z)-Endoxifen. Two key announcements highlight the progress of (Z)-Endoxifen in clinical trials for breast cancer treatment and prevention, indicating a robust pipeline aimed at addressing unmet medical needs in this area.The company announced positive results from the KARISMA trial, which investigated the effects of (Z)-Endoxifen on mammographic breast density a notable factor in assessing breast cancer risk. The trial findings suggest that (Z)-Endoxifen significantly reduces mammographic breast density, pa...
July 22, 2024
Breast cancer continues to be a significant global health concern, particularly among pre-menopausal women with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa Therapeutics, a clinical stage biopharmaceutical company, is working towards addressing this unmet medical need through its Phase 2 EVANGELINE clinical trial. The trial aims to evaluate the efficacy and safety of Atossa s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in combination with exemestane and goserelin as a neoadjuvant treatment for this specific patient population.Enrollment of 80mg Pharmacokinetic Run-In Cohort:Atossa Therapeutics recently announced t...
May 15, 2024
Atossa Therapeutics Pioneers Pathway in Breast Cancer Therapy: A Synergistic Potential Unveiled SEATTLE, WA - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company devoted to addressing significant unmet medical needs in oncology, continues to make strides in the field of breast cancer treatment. The company s recent announcements demonstrate noteworthy progress and a strong foothold in the development of revolutionary oncological therapies focused predominantly on breast cancer. Karisma-Endoxifen Clinical Trial Reaches Landmark Completion On May 15, 2024, Atossa declared a significant milestone with the last patient, last dose in its Phase 2 Karisma-Endoxifen clinical trial....
May 7, 2024
In a recent announcement, Atossa Therapeutics, a renowned clinical stage biopharmaceutical company focusing on breast cancer, has declared its endorsement of the newly released breast cancer screening guidelines by the U.S. Preventive Services Task Force (USPSTF). These guidelines recommend the initiation of breast cancer screening for women at the age of 40. This article aims to present the facts surrounding this development and assess its potential impact on Atossa Therapeutics.Factual Overview:Atossa Therapeutics, Inc., traded as Nasdaq: ATOS, operates as a pioneering biomedical research firm specializing in the development of breakthrough medicines to address unmet medical needs in oncology, with a speci...
April 29, 2024
In a groundbreaking move, Atossa Therapeutics, a clinical-stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology, has announced an expanded research agreement with Weill Cornell Medicine. The focus of this collaboration is to further evaluate the potential synergistic effects between antibody drug conjugates (ADCs) and (Z)-endoxifen, with a specific emphasis on breast cancer treatment.Facts and Findings:Atossa Therapeutics commitment to pushing the boundaries of medical innovation is exemplified by their dedication to improving outcomes for patients with breast cancer. The expanded research agreement with Weill Cornell Medicine signifies the company s focus on exploring the ...
April 9, 2024
SEATTLE, April 09, 2024 - Atossa Therapeutics, a leading clinical stage biopharmaceutical company focused on breast cancer therapeutics, has unveiled encouraging results from its Phase 2 EVANGELINE clinical trial. The trial evaluated the neoadjuvant treatment, (Z)-endoxifen, in pre-menopausal women diagnosed with Grade 1 or 2 Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.The promising safety and efficacy data presented by Atossa Therapeutics have shown a remarkable 100% disease control rate after a 24-week treatment period with (Z)-endoxifen. This ground-breaking finding marks a significant milestone in the quest to combat breast cancer, which affect...
March 19, 2024
The Impact and Success of Five-Year (Z)-Endoxifen Treatment in a Pre-Menopausal Breast Cancer Patient: A Testimony of Efficacy and Safety in ER+/HER2- Subtype Breast cancer remains a major health concern globally, with an urgent need for novel therapeutic approaches addressing the diverse subtypes. Atossa Therapeutics, a clinical-stage biopharmaceutical company focused on breast cancer research, recently shared an update on their FDA-approved expanded access program for the treatment of a pre-menopausal patient with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The patient successfully completed five years of (Z)-endoxifen therapy, exhibiting prom...
February 22, 2024
Atossa Therapeutics, a leading clinical stage biopharmaceutical company focused on addressing unmet needs in oncology, recently announced a significant development in the ongoing RECAST DCIS study. The company disclosed that the first patient has been administered Atossa s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, as part of the study. This groundbreaking study aims to evaluate the suitability of long-term active surveillance without surgery for women diagnosed with Ductal Carcinoma In Situ (DCIS) through neoadjuvant endocrine therapy.DCIS, a non-invasive form of breast cancer, is characterized by the presence of abnormal cells in the milk ducts of the breast. Traditionally, su...
February 7, 2024
Atossa Therapeutics Successfully Completes Enrollment for (Z)-Endoxifen Arm in Phase 2 I-SPY 2 Clinical Trial for Breast Cancer TreatmentSeattle-based biopharmaceutical company, Atossa Therapeutics, has accomplished a significant milestone by announcing the full enrollment of the (Z)-endoxifen arm in its ongoing Phase 2 I-SPY 2 clinical trial. This trial focuses on evaluating the potential of (Z)-endoxifen, Atossa s proprietary Selective Estrogen Receptor Modulator (SERM), as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer.Breast cancer remains a significant health concern globally, with estrogen receptor-positive tumors being the most common subtype. Curre...
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.
Sources:
Atossa Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Atossa Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
